-
公开(公告)号：US20240342202A1
公开(公告)日：2024-10-17
申请号：US18628083
申请日：2024-04-05
Applicant: Unity Biotechnology, Inc.
Inventor： Sharon Klier , Jamie Dananberg
IPC: A61K31/675 , A61K9/00 , A61P27/02
CPC classification number: A61K31/675 , A61K9/0019 , A61K9/0048 , A61P27/02
Abstract: The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others. The method includes treating a patient suffering from a retinal vasculopathy by administering to the patient a therapeutically effective dose of a compound as disclosed herein.
-
公开(公告)号：US20200253991A1
公开(公告)日：2020-08-13
申请号：US16791960
申请日：2020-02-14
Applicant: Unity Biotechnology, Inc.
Inventor： Pam Tsuruda , Jill Hopkins , Harry Sweigard , Yan Poon , Jamie Dananberg , Daniel Marquess , Nathaniel David
IPC: A61K31/635 , A61P27/02
Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
-
公开(公告)号：US20190151337A1
公开(公告)日：2019-05-23
申请号：US16160840
申请日：2018-10-15
Inventor： Pam Tsuruda , Jill Hopkins , Harry Sweigard , Yan Poon , Jamie Dananberg , Daniel Marquess , Nathaniel David
IPC: A61K31/635 , A61K9/00 , A61P27/02
CPC classification number: A61K31/635 , A61K9/0019 , A61K9/0048 , A61K47/10 , A61K47/20 , A61K47/26 , A61P27/02
Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
-
公开(公告)号：US11951115B2
公开(公告)日：2024-04-09
申请号：US17719066
申请日：2022-04-12
Applicant: Unity Biotechnology, Inc.
Inventor： Sharon Klier , Jamie Dananberg
IPC: A61K31/675 , A61K9/00 , A61P27/02
CPC classification number: A61K31/675 , A61K9/0019 , A61K9/0048 , A61P27/02
Abstract: The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others. The method includes treating a patient suffering from a retinal vasculopathy by administering to the patient a therapeutically effective dose of a compound as disclosed herein.
-
Patent Agency Ranking
公开(公告)号：US11865123B2
公开(公告)日：2024-01-09
申请号：US17412003
申请日：2021-08-25
Applicant: Unity Biotechnology, Inc.
Inventor： Pam Tsuruda , Jill Hopkins , Harry Sweigard , Yan Poon , Jamie Dananberg , Daniel Marquess , Nathaniel David
CPC classification number: A61K31/635 , A61P27/02 , A61K9/0019 , A61K9/0048 , A61K47/10 , A61K47/20 , A61K47/26
Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
-
公开(公告)号：US20220331345A1
公开(公告)日：2022-10-20
申请号：US17719066
申请日：2022-04-12
Applicant: Unity Biotechnology, Inc.
Inventor： Sharon Klier , Jamie Dananberg
IPC: A61K31/675 , A61K9/00 , A61P27/02
Abstract: The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others. The method includes treating a patient suffering from a retinal vasculopathy by administering to the patient a therapeutically effective dose of a compound as disclosed herein.
-
公开(公告)号：US20220072015A1
公开(公告)日：2022-03-10
申请号：US17412003
申请日：2021-08-25
Applicant: Unity Biotechnology, Inc.
Inventor： Pam Tsuruda , Jill Hopkins , Harry Sweigard , Yan Poon , Jamie Dananberg , Daniel Marquess , Nathaniel David
IPC: A61K31/635 , A61P27/02
Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
-
公开(公告)号：US11129838B2
公开(公告)日：2021-09-28
申请号：US16791960
申请日：2020-02-14
Applicant: Unity Biotechnology, Inc.
Inventor： Pam Tsuruda , Jill Hopkins , Harry Sweigard , Yan Poon , Jamie Dananberg , Daniel Marquess , Nathaniel David
Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
-
公开(公告)号：US10588916B2
公开(公告)日：2020-03-17
申请号：US16160840
申请日：2018-10-15
Applicant: Unity Biotechnology, Inc.
Inventor： Pam Tsuruda , Jill Hopkins , Harry Sweigard , Yan Poon , Jamie Dananberg , Daniel Marquess , Nathaniel David
Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.016 seconds)
